Meng C. Ngu

Concord, NSW, Australia

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 20 publications

Corrigendum to "Ageing and liver immune cells" [Ageing Res. Rev. 115 (2026) 103039].

Corrigendum to "Ageing and liver immune cells" [Ageing Res. Rev. 115 (2026) 103039].

Journal: Ageing research reviews

Published: February 19, 2026

Ageing and liver immune cells.

Ageing and liver immune cells.

Journal: Ageing research reviews

Published: November 30, 2025

Ageing and Liver Immune Cells.

Ageing and Liver Immune Cells.

Journal: Ageing research reviews

Published: November 30, 2025

Anti-HBs Immune Complex Levels: A Novel Marker of Hepatitis Flare Following Nucleos(t)ide Analog Withdrawal in HBeAg-negative Chronic Hepatitis B.

Anti-HBs Immune Complex Levels: A Novel Marker of Hepatitis Flare Following Nucleos(t)ide Analog Withdrawal in HBeAg-negative Chronic Hepatitis B.

Journal: The Journal of infectious diseases

Published: September 11, 2025

Anti-HBs immune complex levels: A novel marker of hepatitis flare following nucleos(t)ide analogue withdrawal in HBeAg-negative chronic hepatitis B.

Anti-HBs immune complex levels: A novel marker of hepatitis flare following nucleos(t)ide analogue withdrawal in HBeAg-negative chronic hepatitis B.

Journal: The Journal of infectious diseases

Published: September 11, 2025

Liver, ageing and disease.

Liver, ageing and disease.

Journal: Nature reviews. Gastroenterology & hepatology

Published: June 26, 2025

Long-Term Follow-Up of Patients in a Prospective Study of NA Discontinuation Identifies Different Patterns of HBsAg Loss.

Long-Term Follow-Up of Patients in a Prospective Study of NA Discontinuation Identifies Different Patterns of HBsAg Loss.

Journal: Alimentary pharmacology & therapeutics

Published: June 21, 2025

High end-of-treatment hepatitis B core-related antigen levels predict hepatitis flare after stopping nucleot(s)ide analogue therapy.

High end-of-treatment hepatitis B core-related antigen levels predict hepatitis flare after stopping nucleot(s)ide analogue therapy.

Journal: Liver international : official journal of the International Association for the Study of the Liver

Published: January 06, 2024

Oral nanotherapeutic formulation of insulin with reduced episodes of hypoglycaemia.

Oral nanotherapeutic formulation of insulin with reduced episodes of hypoglycaemia.

Journal: Nature nanotechnology

Published: January 03, 2023

Baseline serum HBV RNA is associated with the risk of hepatitis flare after stopping nucleoside analog therapy in HBeAg-negative participants.

Baseline serum HBV RNA is associated with the risk of hepatitis flare after stopping nucleoside analog therapy in HBeAg-negative participants.

Journal: Hepatology communications

Published: December 06, 2022

Hepatitis B Virus Flares After Nucleot(s)ide Analogue Cessation Are Associated With Activation of Toll-Like Receptor Signaling Pathways.

Hepatitis B Virus Flares After Nucleot(s)ide Analogue Cessation Are Associated With Activation of Toll-Like Receptor Signaling Pathways.

Journal: The Journal of infectious diseases

Published: May 23, 2022

Stopping nucleot(s)ide analogues in non-cirrhotic HBeAg-negative chronic hepatitis B patients: HBsAg loss at 96 weeks is associated with low baseline HBsAg levels.

Stopping nucleot(s)ide analogues in non-cirrhotic HBeAg-negative chronic hepatitis B patients: HBsAg loss at 96 weeks is associated with low baseline HBsAg levels.

Journal: Alimentary pharmacology & therapeutics

Published: January 24, 2022

Showing 1-12 of 20

Last Updated: 09/26/2026